Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 03, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the Company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
On March 30, 2007, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust (GSK Trust), transferred 9,157 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on April 02, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Key Facts for Investor Verification
- Three directors (Dr JP Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
- The specific transaction involved the transfer of 9,157 Ordinary Shares from the GSK Trust to employee plan participants.
- The report was signed by Victoria Whyte as the Authorised Signatory on April 03, 2007.